TransCon PTH treatment was well‐tolerated, normalized mean 24‐hour urine calcium excretion, and led to improvements in HRQoL and hypoparathyroidism‐related symptoms, functioning, and well‐being. This evidence concerns the gene PTH and hypoparathyroidism.